Drug/input | Cost (€) | Unit |
---|---|---|
Drug acquisition costs a | ||
SEC 150Â mg | 584.43 | Per dose |
SEC 300Â mg | 1168.86 | Per dose |
CER P 200Â mg | 483.07 | Per prefilled syringe |
ETN 50Â mg | 260.04 | Per prefilled syringe |
ADA 40Â mg | 527.41 | Per prefilled syringe |
INF 100Â mg | 436.06 | Per vial |
GOL 50Â mg | 1086.93 | Per prefilled syringe |
UST 45/90Â mg | 3124.96 | Per prefilled syringe |
APR 10–30 mg | 418.52 | Per 14 day pack |
APR 30Â mg | 14.93 | Per tablet |
ETN biosimilar 50Â mg | 182.02 | Per prefilled syringe |
ADA biosimilar 40Â mg | 369.19 | Per prefilled syringe |
MTX 7.5Â mg | 0.51 | Per dose |
Disease-related costs | ||
Intercept | 297.89 | Per 3Â months |
Cost per HAQ change | 131.61 | Per 1-unit change per 3-months |
Health states | ||
Uncontrolled psoriasis (PASI < 75) | 253.14 | Per 3 months |
Controlled psoriasis (PASI ≥ 75) | 20.46 | Per 3 months |